A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma

• Histologic proof of primary head of pancreas invasive adenocarcinoma managed with a potentially curative resection (i.e., removal of all gross tumor) involving a classic pancreaticoduodenectomy (Whipple) or a pylorus preserving pancreaticoduodenectomy; • Patients with invasive adenocarcinoma that also contains a component of intraductal papillary mucinous neoplasm (IPMN) are eligible; • Interval between definitive tumor-related surgery and 1st step registration between 21-56 days; Patients will be staged according to the 6th edition AJCC staging system with pathologic stage T1-3, N0-1, M-0 being eligible. • Pathologic reporting using the CAPS format is strongly encouraged; • Zubrod performance status 0 or 1; • Before starting therapy the patient should be able to maintain adequate oral nutrition of 1500 calories estimated caloric intake per day and be free of significant nausea and vomiting • Post resection serum CA19-9 < 180 units/mL within 21 days of registration on study; • Creatinine levels < twice the institutional upper limit of normal within 21 days of registration on study; SGOT must be < 2.5 x the institutional upper limit of normal within 21 days of registration on • A tumor tissue block and peripheral blood must be submitted to this study's central tumor bank for correlative studies